Patents by Inventor Benito Munoz

Benito Munoz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING CFTR
    Publication number: 20260078136
    Abstract: The present disclosure is directed to disclosed compounds that modulate e.g., address underlying defects in cellular processing of CFTR activity.
    Type: Application
    Filed: November 24, 2025
    Publication date: March 19, 2026
    Inventors: Benito Munoz, Daniel Parks, Cecilia M. Bastos
  • Fused heterocycles as 5-HT2A receptor agonists
    Patent number: 12486268
    Abstract: The disclosure provides compounds, e.g., compounds of Formula I, and their use in treating medical diseases or disorders, such as neurological disorders. Pharmaceutical compositions and methods of making various azaindole and benzisoxazole compounds are provided. The compounds are contemplated to be modulators of the 5-hydroxytryptamine 2A (5-HT2A) receptor.
    Type: Grant
    Filed: March 5, 2025
    Date of Patent: December 2, 2025
    Assignee: TRANSNEURAL THERAPEUTICS, INC.
    Inventors: Benito Munoz, Urjita H. Shah, Paul Galatsis
  • Fused heterocycles as 5-HT2A receptor agonists
    Patent number: 12459944
    Abstract: The disclosure provides compounds, e.g., compounds of Formula I, and their use in treating medical diseases or disorders, such as neurological disorders. Pharmaceutical compositions and methods of making various azaindole and benzisoxazole compounds are provided. The compounds are contemplated to be modulators of the 5-hydroxytryptamine 2A (5-HT2A) receptor.
    Type: Grant
    Filed: January 19, 2023
    Date of Patent: November 4, 2025
    Assignee: TRANSNEURAL THERAPEUTICS, INC.
    Inventors: Benito Munoz, Urjita H. Shah, Paul Galatsis
  • Kinase inhibitors and methods of use thereof
    Patent number: 12419885
    Abstract: The present invention provides compounds of formula I, pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting kinase (e.g., GSK3 (e.g., GSK3? or GSK3?) or CK1) activity. The present invention further provides methods of using the compounds described herein for treating kinase-mediated disorders, such as neurological diseases, psychiatric disorders, metabolic disorders, and cancer.
    Type: Grant
    Filed: June 10, 2021
    Date of Patent: September 23, 2025
    Assignees: The Broad Institute, Inc., Dana-Farber Cancer Institute, Inc., The General Hospital Corporation
    Inventors: Florence Fevrier Wagner, Jennifer Q. Pan, Sivaraman Dandapani, Andrew Germain, Edward Holson, Benito Munoz, Partha P. Nag, Michael C. Lewis, Stephen J. Haggarty, Joshua A. Bishop, Kimberly Stegmaier, Michel Weiwer, Versha Banerji
  • FUSED HETEROCYCLES AS 5-HT2A RECEPTOR AGONISTS
    Publication number: 20250243199
    Abstract: The disclosure provides compounds, e.g., compounds of Formula I, and their use in treating medical diseases or disorders, such as neurological disorders. Pharmaceutical compositions and methods of making various azaindole and benzisoxazole compounds are provided. The compounds are contemplated to be modulators of the 5-hydroxytryptamine 2A (5-HT2A) receptor.
    Type: Application
    Filed: March 5, 2025
    Publication date: July 31, 2025
    Applicant: TRANSNEURAL THERAPEUTICS, INC.
    Inventors: Benito MUNOZ, Urjita H. SHAH, Paul GALATSIS
  • Proteasome activity enhancing compounds
    Patent number: 12319698
    Abstract: The present invention is directed to compounds having the Formulae (Ia), (Ib), (Ic), or (Id); or the Formulae (II), (IIa), (IIb), or (IIc); or the Formulae (III), (IIIa), (IIIb), (IIIc), (IIId), or (IIIe), and pharmaceutically acceptable salts, solvates, clathrates and prodrugs of any Formula thereof, compositions thereof, and methods for the treatment of a condition associated with a dysfunction in proteostasis.
    Type: Grant
    Filed: November 18, 2022
    Date of Patent: June 3, 2025
    Assignee: Kineta, Inc.
    Inventors: Matthew Cullen, Cecilia M. Bastos, Daniel Parks, Benito Munoz
  • FUSED HETEROCYCLES AS 5-HT2A RECEPTOR AGONISTS
    Publication number: 20240425503
    Abstract: The disclosure provides compounds, e.g., compounds of Formula I, and their use in treating medical diseases or disorders, such as neurological disorders. Pharmaceutical compositions and methods of making various azaindole and benzisoxazole compounds are provided. The compounds are contemplated to be modulators of the 5-hydroxytryptamine 2A (5-H1T2A) receptor.
    Type: Application
    Filed: January 19, 2023
    Publication date: December 26, 2024
    Inventors: Benito MUNOZ, Urjita H. SHAH, Paul GALATSIS
  • COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING CFTR
    Publication number: 20240368198
    Abstract: The present disclosure is directed to disclosed compounds that modulate e.g., address underlying defects in cellular processing of CFTR activity.
    Type: Application
    Filed: July 19, 2024
    Publication date: November 7, 2024
    Inventors: Benito Munoz, Daniel Parks, Cecilia M. Bastos
  • METHODS OF TREATING PULMONARY DISEASES AND DISORDERS
    Publication number: 20240139158
    Abstract: The present disclosure features disclosed method of treating disorders such as COPD, bronchitis and/or asthma using disclosed compounds, optionally together with one or more additional active agents. Contemplated methods include administrating orally or by inhalation to a patient one or more disclosed compounds.
    Type: Application
    Filed: December 15, 2023
    Publication date: May 2, 2024
    Inventors: John Miller, Cecilia M. Bastos, Benito Munoz
  • Proteasome activity enhancing compounds
    Patent number: 11958873
    Abstract: The present invention is directed to compounds having the Formula (I), (II), (III), (IV), and (V), compositions thereof, and methods for the treatment of a condition associated with a dysfunction in proteostasis.
    Type: Grant
    Filed: December 17, 2021
    Date of Patent: April 16, 2024
    Assignee: Kineta, Inc.
    Inventors: Matthew Cullen, Sheila Hauck, Bolin Geng, Megan Foley, Cecilia M. Bastos, Benito Munoz, Markus Haeberlein, Bradley Tait
  • COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING CFTR
    Publication number: 20240109922
    Abstract: The present disclosure is directed to disclosed compounds that modulate e.g., address underlying defects in cellular processing of CFTR activity.
    Type: Application
    Filed: December 4, 2023
    Publication date: April 4, 2024
    Inventors: Benito Munoz, Daniel Parks, Cecilia M. Bastos
  • PROTEASOME ACTIVITY ENHANCING COMPOUNDS
    Publication number: 20230242557
    Abstract: The present invention is directed to compounds having the Formula (I), (II), (III), (IV), and (V), compositions thereof, and methods for the treatment of a condition associated with a dysfunction in proteostasis.
    Type: Application
    Filed: December 17, 2021
    Publication date: August 3, 2023
    Inventors: Matthew Cullen, Sheila Hauck, Bolin Geng, Megan Foley, Cecilia M. Bastos, Benito Munoz, Markus Haeberlein, Bradley Tait
  • PROTEASOME ACTIVITY ENHANCING COMPOUNDS
    Publication number: 20230183256
    Abstract: The present invention is directed to compounds having the Formulae (Ia), (Ib), (Ic), or (Id); or the Formulae (II), (IIa), (IIb), or (IIc); or the Formulae (III), (IIIa), (IIIb), (IIIc), (IIId), or (IIIe), and pharmaceutically acceptable salts, solvates, clathrates and prodrugs of any Formula thereof, compositions thereof, and methods for the treatment of a condition associated with a dysfunction in proteostasis.
    Type: Application
    Filed: November 18, 2022
    Publication date: June 15, 2023
    Inventors: Matthew Cullen, Cecilia M. Bastos, Daniel Parks, Benito Munoz
  • Proteasome activity enhancing compounds
    Patent number: 11560385
    Abstract: The present invention is directed to compounds having the Formulae (Ia), (Ib), (Ic), or (Id); or the Formulae (II), (IIa), (IIb), or (IIc); or the Formulae (III), (IIIa), (IIIb), (IIIc), (IIId), or (IIIe), and pharmaceutically acceptable salts, solvates, clathrates and prodrugs of any Formula thereof, compositions thereof, and methods for the treatment of a condition associated with a dysfunction in proteostasis.
    Type: Grant
    Filed: December 23, 2020
    Date of Patent: January 24, 2023
    Assignee: Proteostasis Therapeutics, Inc.
    Inventors: Matthew Cullen, Cecilia M. Bastos, Daniel Parks, Benito Munoz
  • PROTEASOME ACTIVITY ENHANCING COMPOUNDS
    Publication number: 20220298181
    Abstract: The present invention is directed to compounds having the Formula (I), (II), (III), (IV), and (V), compositions thereof, and methods for the treatment of a condition associated with a dysfunction in proteostasis.
    Type: Application
    Filed: December 17, 2021
    Publication date: September 22, 2022
    Inventors: Matthew Cullen, Sheila Hauck, Bolin Geng, Megan Foley, Cecilia M. Bastos, Benito Munoz, Markus Haeberlein, Bradley Tait
  • COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING CFTR
    Publication number: 20220227739
    Abstract: The present disclosure is directed to disclosed compounds that modulate, e.g., address underlying defects in cellular processing of CFTR activity.
    Type: Application
    Filed: August 25, 2021
    Publication date: July 21, 2022
    Inventors: Benito Munoz, Cecilia M. Bastos, Daniel Parks, David Kombo
  • METHODS OF TREATING PULMONARY DISEASES AND DISORDERS
    Publication number: 20220175735
    Abstract: The present disclosure features disclosed method of treating disorders such as COPD, bronchitis and/or asthma using disclosed compounds, optionally together with one or more additional active agents. Contemplated methods include administrating orally or by inhalation to a patient one or more disclosed compounds.
    Type: Application
    Filed: June 22, 2021
    Publication date: June 9, 2022
    Inventors: John Miller, Cecilia M. Bastos, Benito Munoz
  • KINASE INHIBITORS AND METHODS OF USE THEREOF
    Publication number: 20220160702
    Abstract: The present invention provides compounds of formula I, pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting kinase (e.g., GSK3 (e.g., GSK3? or GSK3?) or CK1) activity. The present invention further provides methods of using the compounds described herein for treating kinase-mediated disorders, such as neurological diseases, psychiatric disorders, metabolic disorders, and cancer.
    Type: Application
    Filed: June 10, 2021
    Publication date: May 26, 2022
    Applicants: The Broad Institute, Inc., Dana-Farber Cancer Institute, Inc., The General Hospital Corporation d/b/a Massachusetts General Hospital
    Inventors: Florence Fevrier Wagner, Jennifer Q. Pan, Sivaraman Dandapani, Andrew Germain, Edward Holson, Benito Munoz, Partha P. Nag, Michael C. Lewis, Stephen J. Haggarty, Joshua A. Bishop, Kimberly Stegmaier, Michel Weiwer, Versha Banerji
  • Compounds and methods for the treatment of malaria
    Patent number: 11325913
    Abstract: Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of malaria.
    Type: Grant
    Filed: June 29, 2020
    Date of Patent: May 10, 2022
    Assignee: THE BROAD INSTITUTE, INC.
    Inventors: Eamon Comer, Nobutaka Kato, Christina Scherer, Jessica Bastien, Jeremy Duvall, Timothy Lewis, Morgane Sayes, Matthew Leighty, Jun Pu, Jennifer Beaudoin, Bertrand Braibant, Benito Munoz
  • Compounds, compositions, and methods for modulating CFTR
    Patent number: 11248010
    Abstract: The present disclosure is directed to disclosed compounds that modulate e.g., address underlying defects in cellular processing of CFTR activity.
    Type: Grant
    Filed: April 14, 2020
    Date of Patent: February 15, 2022
    Assignee: Proteostasis Therapeutics, Inc.
    Inventors: Benito Munoz, Daniel Parks, Cecilia M. Bastos